Profound Medical (TSE:PRN) Hits New 12-Month Low – Time to Sell?

Profound Medical Corp. (TSE:PRN) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$9.62 and last traded at C$9.70, with a volume of 8305 shares changing hands. The stock had previously closed at C$9.97.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised shares of Profound Medical to a “strong-buy” rating in a research note on Saturday, November 9th.

Profound Medical Stock Performance

The company has a quick ratio of 14.98, a current ratio of 8.61 and a debt-to-equity ratio of 16.95. The company has a market cap of C$232.07 million, a PE ratio of -5.71 and a beta of 0.81. The stock’s 50 day simple moving average is C$10.65 and its two-hundred day simple moving average is C$11.40.

Profound Medical (TSE:PRN) last posted its quarterly earnings results on Thursday, November 7th. The company reported C($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.42) by C($0.10). During the same period in the prior year, the firm earned ($0.35) EPS. As a group, research analysts anticipate that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Insider Transactions at Profound Medical

In related news, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of Profound Medical stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of C$10.65 per share, for a total transaction of C$141,996.45. Also, Director Arun Menawat Dr. acquired 20,000 shares of Profound Medical stock in a transaction on Tuesday, December 10th. The shares were bought at an average price of C$10.65 per share, for a total transaction of C$213,000.00. Company insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.